← Eichor
Study identifier: NCT06691555 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt

Condition: Glaucoma · Open Angle Glaucoma (OAG) · POAG  ·  Sponsor: Davinci LTD

PhaseN/A
Planned participants66
Who can joinAll sexes, 40 Years to 90 Years
Healthy volunteersNo

About this study

The goal of this observational study is to evaluate the long-term safety and efficacy of a modified suprachoroidal silicone tube (SST) shunt in treating patients with primary open-angle glaucoma (POAG) and pseudo-exfoliative glaucoma (PXG). The main questions it aims to answer are: Does the SST shunt maintain intraocular pressure (IOP) reduction over an extended follow-up period? What is the effect of the SST shunt on endothelial cell count (ECC) and overall corneal health? Participants will: Undergo intraocular pressure (IOP) measurements Have their endothelial cell count (ECC) evaluated Complete assessments of best corrected visual acuity (BCVA) Be assessed for C/D ratio Be monitored for adverse events or shunt-related complications over time

This description comes directly from the study's public registry record.

Talk to the study team

Nikoloz Labauri, MD. FVRS  ·  +995599003744  ·  nlabauri@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (1)

Davinci Eye Center, LTDTbilisi, GeorgiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06691555